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Stress early in postnatal life may result in long-term memory
deficits and selective loss of hippocampal neurons. The mecha-
nisms involved are poorly understood, but they may involve
molecules and processes in the immature limbic system that are
activated by stressful challenges. We report that administration of
corticotropin-releasing hormone (CRH), the key limbic stress mod-
ulator, to the brains of immature rats reproduced the conse-
quences of early-life stress, reducing memory functions through-
out life. These deficits were associated with progressive loss of
hippocampal CA3 neurons and chronic up-regulation of hippocam-
pal CRH expression. Importantly, they did not require the presence
of stress levels of glucocorticoids. These findings indicate a critical
role for CRH in the mechanisms underlying the long-term effects of
early-life stress on hippocampal integrity and function.
Impairment of hippocampal-mediated learning and memory inadults exposed to early-life stress have been well documented
(1–4), but the mechanisms involved have remained unclear. Long-
term stress in the adult has been shown to result in hippocampal cell
loss, promoting the notion that stress early in life might also alter
hippocampal neuron structure and function permanently. Likely
molecular mechanisms for such long-term effects include signaling
processes that have been found to be induced by stressful challenges
in the immature central nervous system (3, 5–7).
Established stress-induced molecular cascades in hippocam-
pus include activation of glucocorticoid receptors by adrenal-
derived glucocorticoid hormones (8), as well as activation of
receptors for the neuropeptide corticotropin-releasing hormone
(CRH) (9, 10). Saturation of glucocorticoid receptors by ‘‘stress
levels’’ of these hormones can result in hippocampal neuronal
injury (11), but these receptors reside primarily in CA1 (12, 13),
whereas stress-induced damage involves mainly CA3 (8, 11). In
addition, glucocorticoids do not reproduce these effects of stress
on hippocampal integrity when administered in a manner that is
not stressful to the animal (e.g., in food) (14), suggesting that
other factors may be involved (14, 15).
CRH participates in propagation and integration of stress re-
sponses in amygdala and hippocampus (9, 10, 16, 17). For example,
administration of CRH into the lateral ventricles reproduces the
spectrum of behavioral and neuroendocrine responses to stress
(16), and enhanced expression of CRH in both adult (18) and
immature (10) rat hippocampal interneurons by stress-related
neuronal activation has recently been demonstrated. A role for
activation of hippocampal CRH receptors in the mechanisms of the
effects of early-life stress on hippocampal integrity is supported by
several lines of evidence. First, as mentioned, certain stressful
situations increase CRH levels in hippocampus (10, 18). In addition,
CRH has neurotoxic effects on hippocampal neurons (19–22), and
these effects, involving interaction with glutamatergic mechanisms
(21, 23) and enhanced calcium entry (21), may be more pronounced
in the immature hippocampus (21–23). Indeed, our earlier work has
demonstrated that CRH can injure CA3 hippocampal neurons of
the immature rat (21, 22), in a pattern highly reminiscent of that
found for stress-induced injury. This may be due to the increased
numbers of CRH-expressing neurons in developing hippocampus
(24) or to increased CRH-receptor density on CA3 pyramidal
neurons (25–27).
We reasoned that if the mechanisms by which early-life stress
causes long-lasting impairments of hippocampal function and in-
tegrity are mediated by CRH, then early-life administration of the
peptide should reproduce these deficits. Further, these effects
should occur independently of the presence of high plasma glu-
cocorticoid levels. The present study tested these predictions.
Materials and Methods
Animals. Sprague–Dawley-derived male rats (Zivic–Miller, Ze-
lienople, PA) were born in our vivarium and maintained on a 12-h
lightydark cycle with access to unlimited lab chow and water.
Delivery was verified at 12-h intervals (date of birth 5 day 0). Litters
were culled to 12 pups and mixed among experimental groups; thus,
effects of experimental manipulations were compared among lit-
termates. For technical reasons, animals were reared in several
‘‘batches.’’ However, each batch included both control and exper-
imental groups. When weaned, rats were housed 2–3 per cage.
Surgical and Pharmacological Procedures. CRH was administered
into the lateral ventricle of 10-day-old (P10) freely moving rats kept
euthermic on a warming pad, as described (22, 28, 29). Briefly, for
acute experiments, CRH was infused via cannulae implanted 24 h
earlier under halothane anesthesia (’10 minyrat). For long-term
experiments, 0.75 nmol of CRH were administered by using a
semistereotaxic freehand infusion (29). Separation of pups from
the dam (,4 h) was equal for all groups. For examination of acute
CRH-induced injury, a subgroup of rats was given CRH (0.75 nm)
via the cannula twice daily (8 a.m. and 5 p.m.) on P11 and P12 (four
times total). Rats were killed 24 h later (P13) by using pentobarbital
injection and perfused transcardially with 0.9% saline followed by
cold 4% paraformaldehyde.
Adrenalectomy was performed under halothane anesthesia
(’5 minyrat) on P10, 24 h before CRH infusion, via small
bilateral dorsal incisions that were closed with acrylic glue (30).
The completeness of the adrenalectomy was verified by visual
inspection upon death. To permit normal mineralocorticoid
function and based on pilot experiments, adrenalectomized rats
were given aldosterone (s.c., 2 mgy100 gm body weight per day)
during P10–P21 (31). After weaning (P21), corticosterone (10
mgyliter) was added to the drinking solution (0.9% saline) (31,
Abbreviations: CRH, corticotropin-releasing hormone; ISH, in situ hybridization; MWM,
Morris water maze.
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32). This supplementation (‘‘clamping’’) leads to chronic ‘‘basal’’
glucocorticoid levels (31, 32), saturating mineralocorticoid but
not glucocorticoid receptors (12, 13).
Experiments were initiated between 8 a.m. and 10 a.m. to
minimize diurnal variability, were carried out according to
National Institutes of Health guidelines, and approved by the
Institutional Animal Care Committee.
In Situ Hybridization (ISH) Histochemistry for CRH and CRF1 mRNA and
Data Analysis. ISH analyses were performed on tissue from
12-mo-old rats that were killed by rapid decapitation. Brains
were immediately removed and frozen on dry ice. ISH for CRH
mRNA was performed on 20-mm-thick coronal sections as
described (10, 26, 30). For CRF1 mRNA, ISH was performed as
described for cRNA probes (33, 34). For both methods, hybrid-
ized and washed sections were apposed to film (Hyperfilm
b-Max, Amersham Pharmacia) for 7–14 days, and selected
sections were then dipped in emulsion (NTB-2, Eastman Kodak)
and exposed for 3–4 weeks. Semiquantitative analysis of ISH
signal was performed on digitized films as described (30, 34). For
analysis, three matched dorsal hippocampal sections per rat were
sampled by using unbiased methods (34).
BrdUrd Labeling for Detection of Newborn Cells. BrdUrd (Roche
Molecular Biochemicals, 100 mgykg) was injected into 12-mo-
old rats, perfused 48 h later. Brains were sectioned (50 mm),
washed in 2 3 SSC, immersed in 50% formamidey2 3 SSC (2
h, 65°C) to denature DNA, and incubated in 2 M HCl (30 min,
37°C). After neutralization (0.1 M sodium borate), sections were
incubated with anti-BrdUrd (1:400, Accurate Chemicals), fol-
lowed by biotinylated second antibody, and BrdUrd-labeled
nuclei were detected by using the avidin–biotin–peroxidase
reaction with diaminobenzidine as chromogen (10, 24, 25).
Timm’s Stain. The Chafetz (35) modification for frozen tissue was
used. Briefly, thawed, mounted 20-mm coronal sections were
dipped six times (1 dipys) into a 0.37% sulfide solution. Slides were
air-dried (3–5 min) and fixed in 4% paraformaldehyde for 20 min.
After development (1 h), sections were rinsed in double-distilled
water and counterstained with cresyl violet. The extent of aberrant
mossy fiber ‘‘sprouting’’ was evaluated by using a semiquantitative
scale (0–5) for terminal sprouting in the CA3 hippocampal region
(36). Briefly, score criteria were as follows: 0 5 no granules in strata
pyramidale (SP) or oriens (SO); 1 5 occasional discrete granule
bundles in SPySO; 2 5 occasional to moderate granules in SPySO;
3 5 prominent granules in SPySO; 4 5 prominent near-continuous
granule band in SPySO along the entire CA3; and 5 5 continuous
or near-continuous dense granule band in SPySO along the entire
CA3. Scores were determined ‘‘blindly’’ (without knowledge of
treatment) on three matched dorsal hippocampal sectionsyrat per
experimental group. Both hippocampi were analyzed and averaged
to yield the final score.
Morris Water Maze (MWM). The procedure established by Morris
(37) was followed. Briefly, the MWM, a circular pool (diameter,
2 m; depth, 0.6 m) was filled with water (19–21°C) opacified by
powdered milk. A transparent platform (diameter, 13 cm) was
placed in a constant position for each set of trials, in the middle of
one of the pool’s quadrants, 1–2 cm below the water surface to
render it invisible. Tested rats likely obtained visual cues from
objects in the testing room because, in a probe trial, when the
platform was removed they tended to spend more time in the
Fig. 1. Selective neuronal loss and
synaptic reorganization in hippocam-
pal CA3 of adult rats given CRH early
in life. (A) Cell numbers in subregions
of the CA3 pyramidal cell layer from
CRH-treated, vehicle-treated, and na-
ive controls were determined at age 8
and 12 mo. One-way ANOVA with
Tukey’s analysis indicated significant
(P , 0.05; * vs. naive; 1 vs. vehicle-
treated) neuronal loss in CRH-treated
rats, which was selective to CA3C at 8
mo but involved all CA3 subregions by
12 mo. (B) Sections of CA3A pyramidal
cell regions from vehicle- and CRH-
treated rats (killed at 12 mo), sub-
jected to Timm’s stain for visualizing
the high zinc content of mossy fiber
(axons of the CA3-innervating gran-
ule cells) terminals. In CRH-treated
rats, these terminals were abnormally
abundant within CA3 stratum oriens
(so). sl, stratum lucidum. (Scale bar 5
50 mm.)
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quadrant where the platform had previously been located. Rats
were subjected to two consecutive training days (two series of 10
trials) to familiarize them with finding and perching on the hidden
platform that was kept in a fixed location. On the test day (day 3),
the platform was placed in a novel location, and rats were placed in
the water facing the pool wall. Starting positions were randomly
rotated in different quadrants, and rats were subjected to six trials.
For each trial, latency to reach the platform was recorded. Rats
were allowed 60 s to reach the platform and were manually placed
on it if they failed.
Object Recognition. This memory test, relying on spontaneous
exploratory behavior, has been described in detail (38). Briefly,
adult rats were tested in a quiet room, in a 52 3 27 3 21-cm
Plexiglas cage lined with opaque white paper, with the front panel
open to observation. Subjects were given five habituation sessions
(1 h each in the cage with no objects). Test objects were made of
glass and metal (e.g., padlock, light bulb), and duplicate objects
were used in sample and test trials to avoid odor cues. During the
tests, objects were placed in random locations, ’6 cm from the cage
side. The object recognition memory test consisted of giving each
rat one sample trial, during which it was allowed to explore two
objects for 5 min. The test trial was given 24 h later and consisted
of a 5-min epoch in which the rat was presented with a duplicate of
an object from the sample trial and a novel object. In both sample
and test trials, the duration of exploration of each object, defined
as sniffing with the animal’s nose in contact or within 2 cm of the
object, was recorded.
Cell Counts. Cells were counted in paraformaldehyde-fixed, Nissl-
stained sections of the hippocampal CA3 pyramidal cell layer (SP).
CA3 subdivisions were defined by using an imaginary line connect-
ing the tips of the granule cell layer blades, which separated CA3c
(medially) from CA3b (see Fig. 2C). For CA3a, a reticule grid was
centered over the lateral tip of CA3, and cells within 300-mm strips
were counted in both directions. Cells within 300-mm strips along
SP were counted also in CA3b and CA3c. To avoid bias from
potential changes in hippocampal volume associated with CRH
treatment or neuronal loss, hippocampal volume was estimated
according to ref. 39. Briefly, volumes were calculated by summing
areas of one in five coronal hippocampal sections, by using a grid
reticule at low power, and multiplying this value by the distance
between the sections. Profile counts were obtained counting nu-
cleoli in 20-mm sections, thus avoiding stereological confounders
(39–41). Every fifth dorsal hippocampal section between 23.8 and
24.3 Bregma (42) was counted (five sections per rat; 5–7 rats per
group). Bilateral values were obtained ‘‘blindly’’ and averaged
and are reported as absolute number of cells per area counted
(0.18 mm2).
Statistical Considerations. Statistical significance (P , 0.05) was
determined by using a one- or two-way ANOVA or Student’s t
test, as appropriate (Prism GraphPad; San Diego).
Results and Discussion
To determine whether neuronal loss in hippocampal CA3 sub-
fields resulted from early-life administration of CRH, we used
unbiased stereological cell counts. Indeed, numbers of hip-
pocampal CA3 pyramidal cells were reduced in adult rats that
were treated with CRH early in life (P10) (21), compared with
vehicle-treated controls (Fig. 1A). A significant, 17% decrease in
CA3c pyramidal layer neurons was already evident by age 8 mo
(one-way ANOVA with Tukey’s posttest, P , 0.05), and by 12
mo, reduced neuronal numbers were observed throughout the
CA3 pyramidal cell layer (Fig. 1 A). Specifically, at 12 mo,
CRH-treated rats (n 5 12) lost 12%, 10%, and 18% of cells in
CA3a, CA3b, and CA3c, respectively, compared with vehicle-
treated controls (n 5 7). There was also a slight reduction of CA3
cell numbers of each of the experimental groups at the 12-mo
time point compared with the 8-mo counts. This age-related
neuronal loss in the ‘‘middle-aged’’ rat hippocampus has been
described (ref. 43, but see ref. 44). Hippocampal volumes did not
differ between control and experimental groups.
The loss of CA3 pyramidal layer cells was reflected by altered
growth patterns of the mossy fibers, the axons of the dentate
gyrus granule cells that normally innervate these CA3 neurons.
Exuberant growth of mossy fibers into the CA3a stratum oriens
occurred in CRH-treated animals (n 5 7; Timm’s score 2.6 6
0.3) compared with vehicle-treated controls (n 5 4, Timm’s
score 0.3 6 0.3; Fig. 1B) and naive controls (n 5 4, Timm’s score
0.2 6 0.2). This ‘‘sprouting’’ is consistent with, and typical of, a
loss of the normal targets of the mossy fibers (22). Importantly,
the synapses formed by the aberrant mossy fibers on the re-
maining CA3 pyramidal cells are excitatory (glutamatergic),
which could promote further excitotoxic injury to these neurons.
It should be noted that the observed reduction in neuronal
numbers was a true cell loss rather than a suppression of
neurogenesis. Stress, and particularly high levels of glucocorti-
coids, can suppress neurogenesis (45, 46). To determine whether
the rate of neurogenesis differed among experimental groups in
these studies, BrdUrd was injected to both adrenalectomized,
glucocorticoid ‘‘clamped’’ rats and to intact ones to identify
newly born cells. Immunohistological analysis 48 h later revealed
no evidence of altered numbers of BrdUrd-labeled cells in the
dentate gyrus hilus of rats with highly differing glucocorticoid
levels (not shown), suggesting that long-term changes in steroid
Fig. 2. Acute injury of CA3 hippocampal pyramidal cells in P13 rats results
from CRH administration. (A) Shrunken, toluidine blue-stained, injured cells
(arrows) are visible in 1-mm sections from CRH-treated rats, but not in
sections from vehicle-treated controls (B). (C) Subdivisions of CA3 pyrami-
dal cell layer, denoting the CA3byCA3c border. [Scale bars 5 20 mm (A and
B) and 200 mm (C).]
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levels were probably not sufficient to account for the significant
changes in hippocampal cell numbers observed here.
To investigate the potential mechanisms for CA3 pyramidal
cell loss in adult rats treated with CRH early in life, we
determined whether acute CRH administration during that
developmental period damaged hippocampal neurons. CA3
pyramidal neurons in CRH-treated (Fig. 2A), but not in vehicle-
treated (Fig. 2B), rats demonstrated evidence of acute injury
(22). This was confined to the CA3 hippocampal field, a region
particularly rich in mRNA and protein expression of the CRH
receptor subtype (CRF1), which has been shown to mediate the
peptide’s excitatory effects in immature hippocampus (26, 27).
Because neurons damaged by CRH administration comprised
only a minority of hippocampal CA3 cells (22), the significance of
their loss for hippocampal-mediated memory functions was eval-
uated. Using the MWM test (37), rats given CRH early in life
demonstrated worse and progressively declining memory perfor-
mance when tested repeatedly at ages 3, 6, and 10 mo. A trend for
spatial memory impairment was apparent already by 3 mo in
CRH-treated rats (n 5 12, F2,132 5 1.95, P 5 0.15; Fig. 3A), and was
significant both in 6-mo-old (F2,132 5 9.62, P , 0.001; Fig. 3B) and
10-mo-old (F2,132 5 5.53, P , 0.01; Fig. 3C) animals. It should be
noted that at all ages examined, the MWM performance of
vehicle-treated animals (n 5 7) did not differ significantly from that
of naive controls (n 5 6). Further, based on swim speed calculations
and search pattern analyses, there appeared to be no differences in
locomotor activity or motivation among the experimental groups.
In addition, as shown by others (43, 47), an apparent effect of age
was found on the first and second trials; 10-mo-old control animals
took longer to reach the platform in these trials compared with
younger animals.
These data demonstrate that functional hippocampal impair-
ment in rats given CRH early in life arose already at age 3 mo.
Because the same animals were tested repeatedly, and because
behavioral and histological studies were conducted on the same
rats, cell counts could only be obtained upon death (12 mo).
Thus, it is not possible to determine whether the early (3 mo)
cognitive impairment required actual cell death or reflected
cellularymolecular dysfunction that eventually led to cell loss.
Indeed, similar MWM spatial memory deficits in the absence of
hippocampal cell loss (44), or in association with altered pyra-
midal cell morphology (48), have been described.
Because the MWM test entails stressful elements, deficits in
this paradigm might reflect potential consequences of early-life
CRH treatment on the rats’ ability to cope with stress or on their
motivation. Therefore, to further test for hippocampus-
dependent learning deficits, 10-mo-old rats were subjected to the
nonaversive object recognition test, which relies on the fact that
rats with intact hippocampi will spend more time exploring a
novel object compared with one encountered on the previous
day (38). CRH treatment early in life did not influence the
duration of exploration of the two objects on the sample trial day
(day 1, Fig. 3D). However, whereas vehicle controls (n 5 7)
remembered the familiar object on the test day (day 2) and spent
significantly more time exploring the novel one (paired t test, P ,
0.05; Fig. 3D), CRH-treated animals (n 5 10) did not distinguish
between the novel and familiar objects and explored both
equally. Again, the total duration of object exploration did not
differ between the groups on the test day (day 2), indicating that
the motivation of CRH-treated rats was not affected. Taken
together, the results of the object recognition and MWM tests
indicate that CRH-treated rats were deficient in short-term
Fig. 3. Deficient short-term memory skills in adult rats given CRH centrally early in life. (A) CRH-treated rats show a trend toward impaired performance
(increased escape latency) using the MWM at age 3 mo. By 6 (B) and 10 (C) mo, rats treated with CRH early in life take significantly longer to locate the hidden
platform (two-way ANOVA, treatment effect at 6 mo: F2,132 5 9.62, P , 0.001; at 10 mo: F2,132 5 5.53, P , 0.01). This deficit is not attributable to injection
procedures because latencies of vehicle controls were significantly shorter than those of the CRH-treated group and not significantly different from those of naive
controls. Note the progression of the spatial memory acquisition impairment in CRH-treated rats. (D) CRH-treated rats suffer from hippocampus-dependent
memory dysfunction also in the nonaversive, nonstressful object recognition test. On day 1, pattern and duration of exploration of two novel objects were
indistinguishable in CRH- and vehicle-treated rats. However, 24 h later (day 2), vehicle-treated rats discriminated between familiar and novel objects
[remembered the familiar object and explored it for a significantly (*) shorter time; paired t test; P , 0.05], whereas CRH-treated rats did not discern the novel
from the familiar object, indicating impairment of short-term recognition memory. n 5 6–12 rats per group.
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memory functions, and this dysfunction was not attributable to
poor motivation or abnormal responses to stressful situations.
High (‘‘stress’’) levels of glucocorticoids, saturating hippocampal
glucocorticoid receptors, may damage hippocampal neurons (8,
11). Therefore, we determined whether such high glucocorticoid
levels were required for the hippocampal injury and deficits caused
by early-life administration of CRH. Thus, CRH was given to
immature rats rendered devoid of endogenous steroids (adrena-
lectomized), in which glucocorticoid levels were thereafter main-
tained (by supplementing the drinking water) at levels much lower
than those seen during stress (‘‘clamped’’) (30–32). These rats were
tested (at the age of 10 mo) for hippocampal-mediated memory
function and analyzed for hippocampal neuronal cell loss (at 12
mo). As observed with intact animals, CRH given early in life to
Fig. 4. Hippocampal cell loss and short-term memory deficits in 12-mo-old rats given CRH early in life do not require glucocorticoid receptor saturation. (A)
Cells were counted in CA3 pyramidal cell layer subregions of vehicle-treated sham-adrenalectomized (SHAMyADX), of vehicle-treated (VEHyADX), and of
CRH-treated and ADX rats (CRHyADX), which were maintained with chronic low-level glucocorticoids. Significant neuronal loss (P , 0.05; *, vs. SHAMyADX; 1,
vs. VEHyADX; one-way ANOVA with Tukey’s multiple comparison analysis) occurred in CRH-treated rats, confined to CA3A and CA3C. (B) On the second day (day
2, see also Fig. 3D) of the object recognition test, SHAMyADX controls and those with chronic low-level glucocorticoids after early-life adrenalectomy (VEHyADX)
explored the novel object significantly longer (*, P , 0.05; paired t test) than the familiar one, a behavior requiring intact hippocampal function. In contrast,
the CRH-treated group (CRHyADX, also maintained with low plasma glucocorticoid levels) explored both objects for a similar amount of time (i.e., did not remember
the familiar object). This indicates that memory impairment after early-life CRH administration did not require the presence of stress levels of plasma glucocorticoids.
(C) Neither ADX with low-level steroid supplementation nor early-life CRH altered the overall exploration skills and patterns of adult rat. Total exploration time on both
day 1 and day 2 demonstrated the expected individual variability and did not differ significantly among experimental groups (see also Fig. 3D).
Fig. 5. Chronic up-regulation CRH and its
receptor CRF1 mRNAs in hippocampal CA3
pyramidal cells of 12-mo-old rats results from
early-life administration of CRH. (A) En-
hanced CRH mRNA expression in CA3 pyra-
midal cell layer (large arrowheads) in dark-
field micrographs of emulsion-dipped
sections from CRH-treated rats and controls.
(Inset) Silver grains over an eccentrically lo-
cated neuron (arrow) suggest CRH expression
in nonpyramidal cells (interneurons). Small
arrowhead points to an adjacent cell devoid
of silver grains. (B) Semiquantitative analysis
shows enhanced CRH mRNA levels in CA3A of
CRH-treated rats. (C) CRF1 mRNA is signifi-
cantly up-regulated in CA3A and CA3C of
CRH-treated rats. *, significant (P , 0.05) dif-
ference from vehicle and naive controls (one-
way ANOVA with Tukey’s analysis). CTL, con-
trol; so and sl, strata oriens and lucidum,
respectively. [Scale bars 5 100 mm (A) and 25
mm (Inset).]
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animals with clamped levels of glucocorticoids (n 5 5) led to
significant loss (’13–21%) of hippocampal CA3 pyramidal cells
during adulthood as compared with vehicle-treated animals with
similar, clamped glucocorticoid levels (n 5 4) and sham-operated
controls (n 5 4, one-way ANOVA with Tukey’s analysis, P , 0.05;
Fig. 4A). In addition, cognitive impairment in the object recognition
test was still produced by early-life CRH administration even in
animals with low, constant glucocorticoid levels (n 5 10; Fig. 4B),
whereas vehicle-treated adrenalectomized (n 5 7) and sham-
operated rats (n 5 5) did not demonstrate impairments. This deficit
was specific and most likely not associated with decreased motiva-
tion as determined by similar total exploration time on both the
sample trial and testing day (Fig. 4C). Although there was a
discrepancy in exploration behavior on day 2 between CRH-treated
intact animals (which treated the novel object as familiar) and
CRH-treated glucocorticoid clamped animals (which treated the
familiar object as novel), both sets of results importantly suggest
that the animals given CRH early in life could not discriminate
between the two objects. Thus, these data clearly indicate that high
plasma glucocorticoid levels were not required for the anatomical
and cognitive effects of early-life CRH administration.
Both the structural (hippocampal cell loss) and functional con-
sequences of early-life CRH administration appeared to progress
with age. Comparing 8-mo-old to 12-mo-old rats, the loss of
hippocampal CA3 neurons spread from CA3c to other CA3
subfields (Fig. 1A), and memory performance of CRH-treated rats
increasingly diverged from that of vehicle-treated controls (Fig. 3,
compare A vs. C). In considering potential mechanisms for this
progression, we speculated that prolonged up-regulation of CRH
expression in interneurons residing in the CA3 pyramidal cell layer
may promote ongoing neuronal injury and associated memory
impairment (21, 24). Using ISH to determine CRH expression in
hippocampus (10, 30), steady-state CRH mRNA levels in the CA3
hippocampal field were significantly higher in adult animals treated
with CRH early in life (n 5 7), compared with vehicle-treated (n 5
4) or naive (n 5 4) controls (Fig. 5 A and B). Our previous studies
have demonstrated up-regulation of CRH mRNA levels in CA3
hippocampal interneurons upon neuronal activation induced by
some (but not all) early-life stresses (10). It is therefore suggested
that the neuronal stimulation induced by CRH administration to
immature rats (21, 27), which generally reproduces the pattern of
neuronal activation provoked by stress (28, 49), led to chronic
elevation of CRH synthesis in CRH-expressing basket cells (24).
Increased release of the peptide from terminals innervating pyra-
midal cells throughout CA3 would promote excessive activation of
CRH receptors on CA3 pyramidal neurons (25–27). Interestingly,
these receptors were also up-regulated in adult animals given CRH
early in life (Fig. 5C). Increased activation of CRH receptors,
known to enhance glutamatergic neurotransmission (21, 23), cou-
pled with the aberrant mossy-fiber excitatory synapses (Fig. 1B),
may thus contribute to progressive vulnerability of CA3 pyramidal
neurons to excitotoxic injury (8, 19–22) and progressive loss of these
neurons, with consequent functional deficits.
In summary, these studies demonstrate that progressive hip-
pocampal memory dysfunction and cell loss found after early-life
stress result from early-life administration of the stress-
neurohormone, CRH. Loss of CA3 pyramidal cells, as well as
deficits in spatial memory acquisition and in object recognition,
both dependent on hippocampal integrity, were observed. Im-
portantly, cell loss and memory impairment in the object rec-
ognition test were also detected in CRH-treated animals in
which plasma glucocorticoids were clamped at low levels, sug-
gesting that stress levels of these hormones and saturation of
glucocorticoid receptors were not required for these effects.
Thus, the data presented here support the notion that CRH may
be a critical contributor to the processes by which early-life stress
compromises hippocampal structure and function and provide a
rationale for targeting early modulation of hippocampal CRH
for amelioration of certain human stress-related disorders.
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